China-based liquid chromatography product developer Suzhou Sepax Technologies has received $78.4m in a series D round featuring vaccine developer Sinovac Biotech and pharmaceutical firms Sinopharm and Gan & Lee Pharmaceuticals, DealStreetAsia has reported.
Hedge fund manager Hillhouse Capital led the round through its venture capital arm, GL Ventures, and it included Citic Private Equity, Sherpa Healthcare Partners and unnamed others.
Suzhou Sepax is a subsidiary of US-headquartered Sepax Technologies, which was founded in 2002 and which provides products for liquid chromatography, a process which separates out mixtures for functions including industrial purification and medical diagnostics.
Diversified conglomerate Fosun previously took part in Suzhou Sepax’s $31.3m series C round in March this year, investing alongside insurance provider China Life’s Healthcare Fund according to DealStreetAsia. Details of its previous rounds could not be ascertained.
